Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%

RTW Investments disclosed in a May 15, 2026, SEC filing that it bought 16,010,524 shares of Erasca (NASDAQ:ERAS), an estimated $189.23 million trade based on quarterly average pricing.According to a May 15, 2026, SEC filing, RTW Investments increased its holdings in Erasca by 16,010,524 shares during the first quarter of 2026. The estimated transaction value is $189.23 million, calculated using the average closing price for the period. The fund’s quarter-end stake in Erasca was valued at $261.42 million, up $260.88 million from the prior quarter, a figure that incorporates both share purchases and pricing effects.Erasca is a clinical-stage biotechnology company headquartered in San Diego, California, with a focus on developing targeted therapies for cancer driven by the RAS/MAPK pathway. The company leverages a robust pipeline of oral inhibitors designed to address significant unmet needs in oncology. Erasca's strategy emphasizes innovation in precision medicine to achieve durable clinical outcomes in challenging cancer indications.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool